Despite high expression of BCL2 in melanoma compared to other lineages, the response to AZD4320 was not replicated by selective BCL2 inhibition with venetoclax, but rather was recapitulated using the selective BCL-XL inhibitor A-1155463. Here, BCL2L1 is linked to melanoma.